Description: Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
Home Page: aerovatetx.com
AVTE Technical Analysis
930 Winter Street
Waltham,
MA
02116
United States
Phone:
617 443 2400
Officers
| Name | Title |
|---|---|
| Mr. Timothy P. Noyes M.B.A. | CEO & Director |
| Dr. Benjamin T. Dake Ph.D. | Founder, Pres, COO & Sec. |
| Mr. George A. Eldridge | CFO & Treasurer |
| Mr. Hunter Gillies M.D. | Chief Medical Officer |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
| Mr. Timothy J. Pigot | Sr. VP of Commercial |
| Ms. Donna Dea | Head of Regulatory Affairs |
| Dr. Marinus Verwijs Ph.D. | Sr. VP of CMC |
| Ms. Susan Fischer | Sr. VP of Devel. Operations |
| Mr. Stephen Yu | Sr. VP of Quality |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.8598 |
| Price-to-Book MRQ: | 4.5483 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 33 |